150 related articles for article (PubMed ID: 9702935)
1. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
Cohen A; Bregman B; Agabiti Rosei E; Williams B; Dubourg O; Clairefond P; Brudi P; Gosse P; Guéret P
J Hum Hypertens; 1998 Jul; 12(7):479-83. PubMed ID: 9702935
[TBL] [Abstract][Full Text] [Related]
2. Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.
Nyström F; Malmqvist K; Ohman KP; Kahan T
J Hypertens; 2002 Aug; 20(8):1527-33. PubMed ID: 12172314
[TBL] [Abstract][Full Text] [Related]
3. Regression of left ventricular hypertrophy in human hypertension with irbesartan.
Malmqvist K; Kahan T; Edner M; Held C; Hägg A; Lind L; Müller-Brunotte R; Nyström F; Ohman KP; Osbakken MD; Ostergern J
J Hypertens; 2001 Jun; 19(6):1167-76. PubMed ID: 11403367
[TBL] [Abstract][Full Text] [Related]
4. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
[TBL] [Abstract][Full Text] [Related]
5. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
Malmqvist K; Kahan T; Edner M; Bergfeldt L
Am J Cardiol; 2002 Nov; 90(10):1107-12. PubMed ID: 12423712
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Hallberg P; Lind L; Billberger K; Michaelsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Liljedahl U; Syvänen AC; Melhus H
Clin Cardiol; 2004 Mar; 27(3):169-73. PubMed ID: 15049387
[TBL] [Abstract][Full Text] [Related]
7. Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Hallberg P; Karlsson J; Lind L; Michaëlsson K; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Liljedahl U; Syvänen AC; Melhus H
Clin Cardiol; 2004 May; 27(5):287-90. PubMed ID: 15188945
[TBL] [Abstract][Full Text] [Related]
8. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Mörtsell D; Malmqvist K; Held C; Kahan T
J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
[TBL] [Abstract][Full Text] [Related]
10. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Hallberg P; Lind L; Michaëlsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
J Hypertens; 2003 Mar; 21(3):621-4. PubMed ID: 12640257
[TBL] [Abstract][Full Text] [Related]
11. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy.
Müller-Brunotte R; Edner M; Malmqvist K; Kahan T
J Hypertens; 2005 Mar; 23(3):633-40. PubMed ID: 15716707
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Malmqvist K; Ohman KP; Lind L; Nyström F; Kahan T
J Cardiovasc Pharmacol; 2003 Dec; 42(6):719-26. PubMed ID: 14639093
[TBL] [Abstract][Full Text] [Related]
13. The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SILVHIA).
Liljedahl S; Kahan T; Lind L; Arnlöv J
Echocardiography; 2009 Aug; 26(7):753-8. PubMed ID: 19486119
[TBL] [Abstract][Full Text] [Related]
14. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Schiffrin EL; Park JB; Pu Q
J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
[TBL] [Abstract][Full Text] [Related]
15. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
[TBL] [Abstract][Full Text] [Related]
17. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
Am J Hypertens; 2002 May; 15(5):389-93. PubMed ID: 12022239
[TBL] [Abstract][Full Text] [Related]
19. Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment.
Liljedahl U; Kahan T; Malmqvist K; Melhus H; Syvänen AC; Lind L; Kurland L
J Hypertens; 2004 Dec; 22(12):2321-8. PubMed ID: 15614026
[TBL] [Abstract][Full Text] [Related]
20. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
Schneider MP; Klingbeil AU; Delles C; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
